NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
Nanobiotix Announced New Data At ASCO 2924, Showing 48% ORR In Evaluable Anti-PD-1 Naïve Patients (N=25); 28% ORR In Evaluable Anti-PD-1 Resistant Patients (N=25) As Per RECIST 1.1
NANOBIOTIX (NASDAQ:NBTX) today announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoin
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By Anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior Anti-PD-1 Therapy
Analysts Are Bullish on Top Healthcare Stocks: Capitol Health Limited (AU:CAJ), Nanobiotix (GB:0QAV)
Nanobiotix to Unveil NBTXR3 Study Results at ASCO
NANOBIOTIX Announces Presentation of New Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer
Buy Rating Affirmed for Nanobiotix on Strategic Moves and Promising Trial Progress
Nanobiotix Engages at Global Healthcare Conference
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with
Earnings Call Summary | Nanobiotix(NBTX.US) Q1 2024 Earnings Conference
The following is a summary of the Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript:Financial Performance:Nanobiotix reported a Q1 2024 unaudited cash balance of €58.9 million and reassured its
Nanobiotix | 6-K: Report of foreign private issuer (related to financial reporting)
Nanobiotix Reports Q1 Results
Express News | NANOBIOTIX Q1 Cash And Cash Equivalents €58.9M As Of March 31, 2024
Press Release: NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO ---- NASDAQ: NBTX -- the "Company"), a
Nanobiotix Unveils Strategy for Cancer Treatment Growth
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship
Nanobiotix (NBTX) said Tuesday it has aligned with Johnson & Johnson's (JNJ) Janssen Pharmaceutica at their Joint Strategy Committee to transfer the global sponsorship of the phase 3 head and neck can
Nanobiotix Reports Updates For Global NBTXR3 Development Collaboration Highlighting Robust Pipeline And Pathway To Long-Term Growth
Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment of intent to transfer the sponsorshi
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
NANOBIOTIX today announced updates to its corporate strategy designed to enable long-term growth in view of significant progress in the Company's collaboration for the co-development and global commercialization of lead therapeutic candidate NBTXR3.
Nanobiotix Announces Latest Share and Voting Rights Update
Nanobiotix Prepares to Unveil Q1 2024 Results
No Data